Board of Directors
According to the articles of association, the board shall consist of not less than three and not more than nine directors, with no deputies.
The company meets the requirements in the Code, that a majority of the directors must be independent of the company and its senior management and that two within that majority must be independent of major shareholders in the company.
At the General Meeting 2024 it was resolved that the number of directors shall be five.
Ben Toogood
Ben Toogood
Chairman
Board members since 2021. Chairman since 2024.
Born 1976. Bachelor of Pharmacy from Rhodes University. MSc. from University of Witwatersrand and Executive MBA from University of Cambridge.
Other appointments: Head Global Business Development, Sino Biopharmaceuticals Limited, CEO invoX Pharma Limited, Director of Softhale BV and pHion Therapeutics.
Previous assignments: Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories) and Regulatory Affairs Merck Generics (Mylan).
Independent of the company and its executive management. Not independent in relation to the company’s major shareholders.
Holdings in Karolinska Development: 64,001 shares.
Board members since 2021. Chairman since 2024.
Born 1976. Bachelor of Pharmacy from Rhodes University. MSc. from University of Witwatersrand and Executive MBA from University of Cambridge.
Other appointments: Head Global Business Development, Sino Biopharmaceuticals Limited, CEO invoX Pharma Limited, Director of Softhale BV and pHion Therapeutics.
Previous assignments: Head Global BD & M&A Sandoz AG, Group New Business Development Executive Aspen Pharmacare Holdings, Vice President Global Business Development Pharmathen SA, International Licensing Executive Niche Generics (Unichem Laboratories) and Regulatory Affairs Merck Generics (Mylan).
Independent of the company and its executive management. Not independent in relation to the company’s major shareholders.
Holdings in Karolinska Development: 64,001 shares.
Anna Lefevre Skjöldebrand
Anna Lefevre Skjöldebrand
Board member
Board members since 2021.
Born 1969. Master of Laws from Uppsala University.
Other appointments: CEO Swedish Medtech Service AB. Current board assignments include: Sweden Medtech4Health AB (chairwoman), Swecare and St Eriks ögonsjukhus.
Previous assignments include: Head of Legal Swedish Medtech Service AB, Advokat Delphi & Co, Advokat GLS Legal, Jurist Ernst & Young Law, Legal Counsel Front Capital Systems AB. Prevoius board assignments include i.a.: Dedicare AB, E-hälsomyndigheten, SIS AB, Medtech Europe and COCIR, Life Science office of Sweden. She has also been a member of the board in the Board for Public Procurement.
Independent of the company, its executive management and independent in relation to the company’s major shareholders.
No holdings in Karolinska Development.
Board members since 2021.
Born 1969. Master of Laws from Uppsala University.
Other appointments: CEO Swedish Medtech Service AB. Current board assignments include: Sweden Medtech4Health AB (chairwoman), Swecare and St Eriks ögonsjukhus.
Previous assignments include: Head of Legal Swedish Medtech Service AB, Advokat Delphi & Co, Advokat GLS Legal, Jurist Ernst & Young Law, Legal Counsel Front Capital Systems AB. Prevoius board assignments include i.a.: Dedicare AB, E-hälsomyndigheten, SIS AB, Medtech Europe and COCIR, Life Science office of Sweden. She has also been a member of the board in the Board for Public Procurement.
Independent of the company, its executive management and independent in relation to the company’s major shareholders.
No holdings in Karolinska Development.
Philip Duong
Philip Duong
Board member
Board member since 2022.
Born 1990. Bachelor’s degree of Commerce from University of Toronto.
Other appointments: Head of Overseas BD & Alliance at Sino Biopharmaceuticals Limited, member of the board at Treadwell Therapeutics.
Previous assignments: Deutsche Bank AG (Hong Kong Branch).
Independent of the company and its executive management. Not independent in relation to the company's major shareholder.
No holdings in Karolinska Development.
Board member since 2022.
Born 1990. Bachelor’s degree of Commerce from University of Toronto.
Other appointments: Head of Overseas BD & Alliance at Sino Biopharmaceuticals Limited, member of the board at Treadwell Therapeutics.
Previous assignments: Deutsche Bank AG (Hong Kong Branch).
Independent of the company and its executive management. Not independent in relation to the company's major shareholder.
No holdings in Karolinska Development.
Will Zeng
Will Zeng
Board member
Board Member since 2024.
Born 1993. Bachelor’s degree of Economics from the Wharton School of the University of Pennsylvania.
Other appointments: Finance Director of CTTQ Pharma Group and Special Assistant to the chairperson of the board of Sino Biopharmaceutical.
Previous assignments include: Work at Goldman Sachs and Warburg Pincus
Independent of the company and its executive management. Not independent in relation to the company’s major shareholders.
No holdings in Karolinska Development.
Board Member since 2024.
Born 1993. Bachelor’s degree of Economics from the Wharton School of the University of Pennsylvania.
Other appointments: Finance Director of CTTQ Pharma Group and Special Assistant to the chairperson of the board of Sino Biopharmaceutical.
Previous assignments include: Work at Goldman Sachs and Warburg Pincus
Independent of the company and its executive management. Not independent in relation to the company’s major shareholders.
No holdings in Karolinska Development.
